STX500

**STX500** is a degradable molecular glue degrader developed by SyntheX, Inc. using their ToRNeDO platform, which identifies molecular glues that induce proximity between a target neosubstrate and an E3 ubiquitin ligase for targeted protein degradation. It specifically targets **Cbl-b (E3 ubiquitin-protein ligase CBL-B)**, an inhibitor of T-cell activation, to enhance antitumor immune responses by promoting T-cell function in the tumor microenvironment. Primarily aimed at **oncology indications** such as neoplasms, it is part of SyntheX's preclinical pipeline focused on immuno-oncology through protein degradation, though development has been marked as discontinued in some databases.[1]